A Double-Blind, Escalating Dose Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Evaluation of Repeat Doses of EVP-6308 or Placebo in Subjects With Schizophrenia on a Stable Antipsychotic Regimen
Phase of Trial: Phase I
Latest Information Update: 11 Jan 2015
Price : $35 *
At a glance
- Drugs FRM 6308 (Primary)
- Indications Schizophrenia
- Focus Adverse reactions
- Sponsors FORUM Pharmaceuticals
- 09 Oct 2014 Planned primary completion date changed from 1 Feb 2015 to 1 Nov 2014 as reported by ClinicalTrials.gov.
- 09 Oct 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 27 Feb 2014 Planned End Date changed from 1 Nov 2014 to 1 Feb 2015, as per ClinicalTrials.gov record.